vs
Side-by-side financial comparison of AtriCure, Inc. (ATRC) and CarParts.com, Inc. (PRTS). Click either name above to swap in a different company.
AtriCure, Inc. is the larger business by last-quarter revenue ($141.2M vs $120.4M, roughly 1.2× CarParts.com, Inc.). AtriCure, Inc. runs the higher net margin — 0.1% vs -9.6%, a 9.7% gap on every dollar of revenue. On growth, AtriCure, Inc. posted the faster year-over-year revenue change (14.3% vs -9.8%). Over the past eight quarters, AtriCure, Inc.'s revenue compounded faster (10.2% CAGR vs -8.6%).
AtriCure, Inc. is a global medical device company specializing in the research, development, and manufacturing of innovative surgical tools and therapeutic solutions for treating atrial fibrillation and associated cardiac conditions. Its core customers include hospitals, cardiac surgery centers, and healthcare providers across North America, Europe, and the Asia Pacific region, with products designed to support safer, more effective minimally invasive cardiac procedures.
Genuine Parts Company (GPC) is an American automotive and industrial parts distributor based in Atlanta, Georgia. Established by brothers Carlyle and Malcolm Fraser in 1928, the company has approximately 60,000 employees. In addition to the United States, GPC has operated in Australasia, Belgium, Canada, France, Germany, Mexico, the Netherlands, Poland, and the United Kingdom. GPC's subsidiaries include industrial parts distributor Motion as well as NAPA Auto Parts, which primarily sells part...
ATRC vs PRTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $141.2M | $120.4M |
| Net Profit | $108.0K | $-11.6M |
| Gross Margin | 77.4% | 33.2% |
| Operating Margin | 23.0% | — |
| Net Margin | 0.1% | -9.6% |
| Revenue YoY | 14.3% | -9.8% |
| Net Profit YoY | — | 25.0% |
| EPS (diluted) | $0.00 | $-0.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $141.2M | — | ||
| Q4 25 | $140.5M | $120.4M | ||
| Q3 25 | $134.3M | $127.8M | ||
| Q2 25 | $136.1M | $151.9M | ||
| Q1 25 | $123.6M | $147.4M | ||
| Q4 24 | $124.3M | $133.5M | ||
| Q3 24 | $115.9M | $144.8M | ||
| Q2 24 | $116.3M | $144.3M |
| Q1 26 | $108.0K | — | ||
| Q4 25 | — | $-11.6M | ||
| Q3 25 | $-267.0K | $-10.9M | ||
| Q2 25 | $-6.2M | $-12.7M | ||
| Q1 25 | $-6.7M | $-15.3M | ||
| Q4 24 | — | $-15.4M | ||
| Q3 24 | $-7.9M | $-10.0M | ||
| Q2 24 | $-8.0M | $-8.7M |
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | 33.2% | ||
| Q3 25 | 75.5% | 33.1% | ||
| Q2 25 | 74.5% | 32.8% | ||
| Q1 25 | 74.9% | 32.1% | ||
| Q4 24 | 74.5% | 32.5% | ||
| Q3 24 | 74.9% | 35.2% | ||
| Q2 24 | 74.7% | 33.5% |
| Q1 26 | 23.0% | — | ||
| Q4 25 | 1.8% | — | ||
| Q3 25 | 0.2% | -7.9% | ||
| Q2 25 | -4.5% | -8.2% | ||
| Q1 25 | -4.8% | -10.3% | ||
| Q4 24 | -11.7% | -11.6% | ||
| Q3 24 | -6.4% | -6.9% | ||
| Q2 24 | -6.2% | -6.0% |
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | -9.6% | ||
| Q3 25 | -0.2% | -8.5% | ||
| Q2 25 | -4.5% | -8.4% | ||
| Q1 25 | -5.5% | -10.4% | ||
| Q4 24 | — | -11.5% | ||
| Q3 24 | -6.8% | -6.9% | ||
| Q2 24 | -6.9% | -6.0% |
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | $-0.82 | ||
| Q3 25 | $-0.01 | $-0.19 | ||
| Q2 25 | $-0.13 | $-0.23 | ||
| Q1 25 | $-0.14 | $-0.27 | ||
| Q4 24 | $-0.33 | $-0.28 | ||
| Q3 24 | $-0.17 | $-0.17 | ||
| Q2 24 | $-0.17 | $-0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $146.2M | $25.8M |
| Total DebtLower is stronger | $61.0M | — |
| Stockholders' EquityBook value | $491.7M | $53.5M |
| Total Assets | $644.0M | $184.9M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | $25.8M | ||
| Q3 25 | $147.9M | — | ||
| Q2 25 | $117.8M | — | ||
| Q1 25 | $99.9M | — | ||
| Q4 24 | $122.7M | — | ||
| Q3 24 | $130.3M | — | ||
| Q2 24 | $114.0M | — |
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — |
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | $53.5M | ||
| Q3 25 | $476.5M | $64.2M | ||
| Q2 25 | $464.5M | $62.4M | ||
| Q1 25 | $454.6M | $72.8M | ||
| Q4 24 | $461.0M | $85.2M | ||
| Q3 24 | $465.0M | $97.2M | ||
| Q2 24 | $462.1M | $103.9M |
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | $184.9M | ||
| Q3 25 | $635.4M | $200.3M | ||
| Q2 25 | $608.8M | $189.6M | ||
| Q1 25 | $591.6M | $216.5M | ||
| Q4 24 | $609.3M | $210.6M | ||
| Q3 24 | $615.1M | $227.6M | ||
| Q2 24 | $597.3M | $238.0M |
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
PRTS
Segment breakdown not available.
